Evidence based article

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913335/

My article is about optimizing the benefits of biologic therapy in patients with ulcerative colitis. The anti-TNF alpha (antitumor necrosis factor alpha), “act by binding to the proinflammatory cytokine TNF alpha.” The drugs that are mentioned in the article as most commonly used are infliximab (Remicade) and adalimumab (Humira). Infliximab is given via infusions in the doctor’s office and Humira is given subcutaneously and is typically given every week to every 2 weeks. Golimumab and vedolizimumab were also mentioned as alternative therapies but the most preferred treatments were infliximab and adalimumab. Patients that received these treatments and did not develop antibodies that required them to quit taking the medication, had a higher incidence of remission and a lower incidence of requiring a colectomy. The ultimate goal of the biologic therapy is mucosal healing and de-escalation of therapy. The physician has to have a good patient history in order to prescribe the correct biologic therapy treatment for the patient with ulcerative colitis. They also need to follow-up with the patient to determine if the treatment has been effective by collecting the proper blood work such as C-Reactive Protein and serum albumin levels. Also following up with the proper testing such as colonoscopies and other endoscopic testing is essential to monitor the effectiveness of the drug therapy.